Positive Phase IIb Topline Clinical Data for Celgene Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis
Placebo-controlled, four-arm study met its primary endpointat 16 weeksStudy demonstrates PASI-75 of 41% for apremilast 30mg twicedaily compared to 6% for placebo (p<0.001) at 16 weeks;apremilast was also generally well-toleratedPivotal phase…
December 15th, 2009
Posted in
Drug